CA
NZ
UK
AU
IND
US
…
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer's disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Premier Biomedical Inc is a publicly quoted company on the OTC Pink market that identifies with the biomedical sector. Public filings contain limited operational and financial detail, so major long-term growth drivers are not discernible from available records and investors may need to obtain direct company disclosures to assess prospects.
Primary risks include extreme illiquidity typical of Pink-sheet listings, a high likelihood of equity dilution from future financings, uncertain operating performance or commercial traction, and regulatory and execution risk common to small biomedical issuers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.09M | -0.10M | -0.20M | -0.05M | -0.04M |
| Net income | -0.09M | -0.10M | -0.20M | -0.05M | -0.04M |
| Gross profit | - | - | - | -0.00M | -0.00M |
| Ebit | - | - | -0.17M | -0.02M | -0.01M |
| Ebitda | -0.09M | -0.06M | -0.00M | -0.02M | -0.01M |
| Depreciation and amortization | - | - | 0.17M | 0.00M | 0.00M |
| Operating income | -0.09M | -0.06M | -0.17M | -0.02M | -0.01M |
| Other operating expenses | 0.09M | 0.06M | 0.17M | 0.02M | 0.01M |
| Interest expense | - | 0.04M | 0.03M | 0.03M | 0.03M |
| Income tax expense | - | - | -0.17M | 0.00M | 0.00M |
| Total operating expenses | 0.09M | 0.06M | 0.17M | 0.02M | 0.01M |
| Cost of revenue | - | - | - | 0.00M | 0.00M |
| Total other income expense net | - | -0.04M | -0.03M | -0.03M | -0.03M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.00M | 0.00M | 0.01M | 0.00M | 0.00M |
| Total liab | 2.61M | 2.58M | 2.49M | 2.28M | 2.25M |
| Total stockholder equity | -2.61M | -2.58M | -2.48M | -2.28M | -2.25M |
| Other current liab | 1.55M | 1.61M | 1.92M | 1.85M | 1.60M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -18.04M | -17.95M | -17.86M | -17.65M | -17.60M |
| Other assets | - | 0.00M | - | - | - |
| Cash | 0.00M | 0.00M | 0.00M | - | - |
| Total current liabilities | 2.61M | 2.58M | 2.49M | 2.28M | 2.25M |
| Net debt | 0.75M | 0.61M | 0.56M | 0.44M | 0.44M |
| Short term debt | 0.75M | 0.61M | 0.57M | 0.44M | 0.44M |
| Short long term debt total | 0.75M | 0.61M | 0.57M | 0.44M | 0.44M |
| Other stockholder equity | 15.42M | 15.36M | 15.37M | 15.37M | 15.35M |
| Total current assets | 0.00M | 0.00M | 0.00M | - | - |
| Accounts payable | 0.31M | 0.36M | - | - | 0.22M |
| Accumulated other comprehensive income | - | - | -0.01M | -0.01M | -0.01M |
| Non currrent assets other | - | 0.00M | 0.00M | - | - |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | - | - | - | - | -0.00M |
| Change to liabilities | - | - | - | - | -0.07M |
| Total cashflows from investing activities | - | - | - | - | -0.00M |
| Net borrowings | - | - | - | - | 0.33M |
| Total cash from financing activities | 0.18M | - | 0.01M | - | 0.33M |
| Change to operating activities | - | - | - | - | 0.11M |
| Net income | -0.20M | -0.05M | -0.04M | -0.40M | -0.37M |
| Change in cash | 0.00M | 0.00M | - | -0.07M | -0.02M |
| Begin period cash flow | 0.00M | - | - | 0.07M | 0.09M |
| End period cash flow | 0.00M | 0.00M | - | - | 0.07M |
| Total cash from operating activities | -0.17M | 0.00M | -0.01M | -0.07M | -0.34M |
| Issuance of capital stock | - | - | - | - | 0.00M |
| Depreciation | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | - | - | - | 0.00M | 0.01M |
| Change to account receivables | - | - | - | 0.00M | 0.00M |
| Other cashflows from financing activities | 0.18M | - | 0.01M | - | -0.00M |
| Change to netincome | - | - | - | - | -0.35M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.03M | 0.05M | 0.03M | 0.07M | 0.05M |
| Stock based compensation | - | - | - | - | 0.00M |
| Other non cash items | - | 0.00M | 0.00M | 0.26M | -0.02M |
| Free cash flow | -0.17M | 0.00M | -0.01M | -0.07M | -0.35M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BIEI Premier Biomedical Inc |
-0.00 12.50% |
0.00 | - | - | 36.41 | - | 112.03 | 76.52 |
| MKKGY Merck KGaA ADR |
0.03 0.09% |
33.71 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
0.04 0.02% |
169.25 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.10 0.45% |
20.82 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
4.63 12.39% |
42.00 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer's disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.
| Name | Title | Year Born |
|---|---|---|
| Mr. David Caplan | Pres, Chairman of Directors, Sec. & Treasurer | NA |
| Mr. Carl Eller | Marketing & Planning Vice-Pres | NA |
| Mr. David Caplan | President, Chairman of the Board of Directors, Secretary & Treasurer | NA |
| Mr. Gustavo Carreño | Chief Technology Officer | NA |
| Mr. Carl Eller | Marketing & Planning Vice-President | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.40%
Communication Services
+0.50%
Consumer Cyclical
+1.37%
Consumer Defensive
+0.86%
Energy
-2.31%
Financial Services
+0.99%
Financials
+0.52%
Healthcare
-0.64%
Industrials
+0.63%
Real Estate
+0.65%
Technology
-0.08%
Utilities
+0.01%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...